Pramlintide
Symlin (amylin analog)
Pramlintide (Symlin (amylin analog)) is a metabolic & fat loss research compound. Synthetic amylin analog — slows gastric emptying, suppresses glucagon, and curbs appetite; the original amylin drug, dosed at meals.
Pramlintide quick facts
| Reported research dose | 60mcg-120mcg |
| Route | Subq |
| Frequency | With meals |
| Half-life | ~48 min |
| Forms | Injectable |
| Evidence level | FDA-approved; human |
The OG amylin — short-acting and meal-timed, unlike the weekly cagrilintide/eloralintide.
How Pramlintide works
Synthetic amylin analog — slows gastric emptying, suppresses glucagon, and curbs appetite; the original amylin drug, dosed at meals.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Can you actually get Pramlintide?
Symlin — used alongside mealtime insulin under specialist care.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Pramlintide
Graded by what exists behind each claim.
✅ Clinically validated
- FDA-approved as Symlin for type 1 and type 2 diabetes on insulin, with trials showing reduced post-meal glucose excursions and modest weight loss.
- It carries a boxed warning for severe hypoglycemia when used with insulin — the real clinical constraint, and the reason it is prescribed far less than its mechanism deserves.
📊 Correlative data
- Limited uptake despite approval, largely because it requires separate injections at every meal alongside insulin. Nausea is common and dose-limiting.
- Renewed interest is mechanistic, not clinical: amylin agonism is the basis of cagrilintide and the newer dual agents, so this is the proof of concept the class is built on.
🧪 Theoretical / extrapolated
- A synthetic analog of amylin, a hormone co-secreted with insulin from beta cells. It slows gastric emptying, suppresses inappropriate glucagon release after meals, and promotes satiety — three actions insulin alone does not cover.
- Native human amylin aggregates and cannot be formulated; substituting three prolines from rat amylin fixed that. It is one of the cleaner examples of solving a physical-chemistry problem to rescue a drug.
- Amylin acts on a different satiety pathway from GLP-1, which is why combining the two produces more weight loss than either alone rather than just more of the same.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Pramlintide actually does
Start with the fact that decides everything else on this page: there is no amylin receptor gene. The amylin receptors are built rather than encoded — the calcitonin receptor supplies the core, and a receptor-activity-modifying protein docks onto it and reshapes its extracellular face Boyle 2022. CTR plus RAMP1 is AMY1. CTR plus RAMP3 is AMY3. Take the RAMP away and what is left is a calcitonin receptor.
That is not a technicality. It means every amylin drug ever made is a calcitonin-receptor drug wearing an accessory protein, and that ‘selectivity’ in this class is not selectivity between two different proteins — it is selectivity between two dressings of the same protein. When Lilly reports that eloralintide is 12-fold selective for human AMY1R over the calcitonin receptor Briere 2025, the honest reading is that the best-engineered molecule in this family separates them by about one order of magnitude. Pramlintide has no published selectivity ratio at all.
What the hormone does, in order. Amylin is co-secreted with insulin from the beta cell in response to nutrients, and it does three things insulin does not: it is a physiological control of meal-ending satiation, it limits the rate of gastric emptying, and it suppresses postprandial glucagon Boyle 2022. Those actions are mediated by direct brain activation, with the caudal hindbrain the most prominent site Boyle 2022 — which is to say the drug does not have to cross the blood-brain barrier, because the part of the brain it acts on sits outside it.
Why pramlintide is not amylin. Human amylin is amyloidogenic. It stacks into beta-sheet fibrils, which is what islet amyloid in type 2 diabetes is made of, and a peptide that fibrillates in the vial is not a drug — the amyloidogenic property is named as one of the specific reasons amylin has been so hard to translate Volcansek 2025. Rat amylin does not do this. The fix was to borrow it: three proline substitutions at residues 25, 28 and 29 taken from the rat sequence. Proline breaks a beta-sheet by construction — its ring locks the backbone and it has no amide hydrogen to donate — so three of them placed through the aggregation-prone stretch make the fibril geometrically impossible.
This is a physical-chemistry fix, and it has a physical-chemistry cost that shows up in the syringe. The resulting peptide is formulated acidic, at roughly pH 4, while rapid-acting insulin is formulated near neutral. They cannot share a syringe, which is why the drug that is supposed to be given at every meal alongside insulin has to be a second injection at a separate site. The reason this compound never got traction is written into its own chemistry.
One more property, because it is the reason the whole field came back to amylin: amylin is a sensitizer to the catabolic actions of leptin Boyle 2022. Nothing else in this cohort has that claim attached to it.
Cell, rodent, human — and where it stops
Step one, the receptor, in cell lines. The clarification of amylin receptor structure — calcitonin core plus RAMP — is what made a broad pharmacological profile designable in the first place Boyle 2022. Everything downstream inherits an uncertainty from it: a transfected cell expressing a chosen CTR:RAMP ratio is not a hindbrain neuron, where the ratio is whatever the tissue makes.
Step two, in rats, and this is the study that explains what the drug does to behavior. Male rats, intraperitoneal pramlintide or vehicle twice daily for 1 week, with chow intake, meal patterns and body weight monitored throughout Kern 2024. Pramlintide cut chow intake mainly by suppressing meal size, with matching reductions in meal duration on several days, and fewer effects on meal number or feeding rate. Weight gain over the week fell. Read that carefully, because it is a mechanism statement, not a weight statement: this drug does not make you eat fewer times. It makes each meal end earlier.
Step three, in people, where it is approved and where the evidence is thinner than the approval suggests. Pramlintide is the first and currently the only approved injectable short-acting selective amylin analog, given as an adjunct to insulin, and it improves both postprandial and overall glycemic control in type 1 and type 2 diabetes Volcansek 2025. Then look at how it ranks when it is pooled against everything else used the same way. A network meta-analysis of 58 randomized trials and 13,216 adults with type 1 diabetes found that SGLT inhibitors, liraglutide, glibenclamide, acarbose and metformin reduced HbA1c against placebo Avgerinos 2021. Pramlintide is not on that list. What pramlintide did do in that analysis was increase the incidence of nausea.
Step four, the null result nobody quotes. Post-bariatric hypoglycemia after gastric bypass is the condition pramlintide’s mechanism was tailor-made for: slow gastric emptying, cut postprandial glucagon, flatten the glucose spike, and the reactive insulin surge that causes the hypoglycemia should not happen. An 8-week open-label study escalated to a maximum of 120 micrograms three times daily (mean 69 ± 32 mcg); 23 people were assessed, 20 received at least one dose and 14 completed Sheehan 2022. The result was nothing. No difference in mixed-meal glucose, glucagon or insulin. No change in satiety or dumping scores. No change in the frequency of low sensor glucose values, though with substantial variation between individuals. Three of the drug’s four advertised actions were measured directly and none of them moved.
The obstacles, and they are specific. (1) The exposure shape is the drug. A roughly 48-minute half-life means the pharmacology is three short pulses a day with long empty gaps, and every newer amylin analog is the same receptor held at a steady concentration for a week. Nobody has shown those two are the same pharmacology. (2) The rodent readout has no human counterpart. Meal size Kern 2024 is measured by continuous cage monitoring; the human trials measured HbA1c and body weight, and no registered pramlintide trial has ever reported meal size as an endpoint. (3) The comparator is unfavorable and always has been. Three injections a day for a drug that did not separate from placebo on HbA1c in the pooled type 1 analysis Avgerinos 2021 is the reason uptake stayed low, not a marketing failure. (4) The one condition where the mechanism should have been decisive produced a clean negative Sheehan 2022.
And the reason the page is not a dismissal. Every weekly amylin agonist now in development exists because this molecule proved in humans that amylin agonism causes satiety and weight loss. Pramlintide is the proof of concept the class is built on Volcansek 2025, and the field left it not because it failed but because it was inconvenient.
Pramlintide pharmacokinetics — how much of it actually gets in
The catalog says ~48 min. That number is the whole clinical story, so it is worth taking apart.
What degrades it. Pramlintide is a 37-residue peptide with no acylation, no albumin binder and no Fc fusion — the three prolines fix aggregation and do nothing for duration. So it is cleared the way an unmodified small peptide is cleared: renal filtration and handling, plus proteolysis by circulating and brush-border peptidases. Nothing in its structure slows either step down.
What a 48-minute half-life actually means at the dose. Five half-lives is four hours, so a 60–120 mcg mealtime dose is essentially gone before the next meal. That is deliberate: the drug is supposed to cover a meal and then leave. Set it against the weekly amylin agonists in this same catalog, where once-weekly dosing implies a half-life around 168 hours — roughly a 200-fold difference in residence time from the same receptor family.
The oral barrier, which is absolute here and for an extra reason. Swallowed, a 37-residue peptide meets gastric acid, then pancreatic proteases, then brush-border peptidases; there is no transporter that carries an intact 37-mer across the enterocyte, and hepatic first-pass extraction would remove what crossed. Oral bioavailability is not low, it is effectively zero, and oral amylin formulations are still listed as a research goal rather than a product Volcansek 2025. The extra reason is the aggregation problem: an acidic gastric environment is exactly where an amyloidogenic peptide would be most inclined to fibrillate.
The injectable route, and the constraint it does not remove. Every dose is subcutaneous, at a meal, at a site away from the insulin injection, because the two formulations sit at different pH and cannot be mixed. Subcutaneous administration removes the gut and the first-pass liver. It does not remove the peptidases, it does not extend the 48 minutes, and it does not reduce the injection count from three a day to anything smaller.
What would have to be true, and how you would know it was not
Four predictions. The first two argue against the compound, and the first one is the reason most people who try it stop.
1. HbA1c will barely move on pramlintide alone, and that is the prediction to test first. In the pooled type 1 network of 58 trials and 13,216 participants, the drugs that separated from placebo on HbA1c were SGLT inhibitors, liraglutide, glibenclamide, acarbose and metformin — not this one Avgerinos 2021. So: draw HbA1c (Hemoglobin A1c) at baseline and again at 12 weeks and expect less than about 0.4% of movement attributable to the drug itself. Because HbA1c averages three months and this compound works on the two hours after a meal, add fructosamine at 2–3 weeks, which integrates over a fortnight and will catch a postprandial change HbA1c smooths away. If fructosamine falls while HbA1c does not, the drug is doing exactly what its mechanism says and exactly as little as its trials say.
2. Fasting insulin should not fall from the drug. Amylin does not stimulate or suppress basal insulin secretion; what it changes is the size of the postprandial excursion Boyle 2022. So a falling Fasting Insulin or C-peptide on this compound is weight loss and diet, not amylin agonism. Baseline and 12 weeks, drawn fasted, on the same schedule.
3. Meal size, not meal count, is the observable. The rodent study is unusually precise about this: intake fell through smaller meals and shorter meals, with little change in how often the animals ate Kern 2024. The human version costs nothing — log grams or portions per eating occasion for a week before and a week during. If the number of eating occasions falls and the size does not, whatever is happening is not the published amylin mechanism.
4. Lipase and amylase should stay flat, and if they do not the cause is elsewhere. Pramlintide’s actions are hindbrain and gastric; nothing in the published mechanism points at the pancreatic acinar cell Boyle 2022. Baseline and 12 weeks. Rising lipase or amylase on a drug whose mechanism does not predict it is a finding worth chasing rather than a class expectation to shrug at.
What nobody has tested yet
Four experiments, and the first one is a phone and a notebook.
1. Nobody has measured meal size in a human on pramlintide. It is the mechanism the rodent work identifies Kern 2024 and it has never appeared as an endpoint in a registered human trial, which have measured HbA1c and body weight instead. A photographed food log across a 2-week baseline and a 4-week treatment window, scored for grams per occasion and occasions per day, would produce the first human test of the actual mechanism — and it needs no laboratory.
2. Nobody has run short-acting against long-acting amylin at matched total exposure. Three pulses a day for a week and one steady week-long concentration deliver comparable total drug on completely different schedules, and the entire commercial argument for the weekly agents assumes the schedule does not matter. Amylin’s physiological role is meal-ending satiation Boyle 2022, which is a per-meal signal — so the assumption is not obviously safe, and no crossover trial has tested it.
3. Nobody has measured bone turnover or calcium handling on chronic amylin agonism. The receptor is a calcitonin receptor with an accessory protein attached Boyle 2022; calcitonin’s own job is to inhibit osteoclasts and lower serum calcium. A drug that occupies that core receptor three times a day for years has an obvious bone question attached to it and no published answer in either direction.
4. Nobody has asked whether the leptin-sensitizing effect survives weight loss. Amylin sensitizes to the catabolic actions of leptin Boyle 2022, and leptin falls as fat mass falls. If the sensitization is what produces the effect, the effect should weaken precisely as the weight comes off — a self-limiting drug. That prediction has never been tested in a person, and it applies to every amylin analog now in development, not just to this one.
Pramlintide — its own safety story, not its class's
The class block on this page is written for GLP-1 receptor agonists. Pramlintide is not one, and three of its four biggest risks are not in that block at all.
1. The boxed warning is a timing collision, not a potency problem. Pramlintide carries a boxed warning for severe hypoglycemia when used with insulin, concentrated in the first three hours after a dose, which is why the label requires the mealtime insulin dose to be cut by half at initiation. The mechanism is worth stating precisely because it tells you exactly who is at risk: pramlintide does not lower glucose much itself — it slows the arrival of glucose by slowing gastric emptying Boyle 2022. Rapid-acting insulin injected on the old schedule then peaks into a meal that has not arrived. The risk belongs to the insulin, uncovered. Someone not taking insulin or a sulfonylurea is not exposed to it; someone taking either and not re-timing the dose is exposed to all of it.
And the counterweight, because both facts are true: in the pooled type 1 network of 58 trials and 13,216 participants, no drug, pramlintide included, increased the incidence of severe hypoglycemia Avgerinos 2021. Under protocol, with insulin reduced on schedule, the signal does not appear. The boxed warning describes what happens when it is not.
2. Nausea is dose-limiting and it is measured. Pramlintide increased the incidence of nausea in the same pooled analysis Avgerinos 2021. This is not the GLP-1 nausea story wearing a different name — amylin slows gastric emptying by its own hindbrain route Boyle 2022, and the practical consequence is identical: titrate into it or stop.
3. The risk that belongs to this molecule alone: migraine. Amylin is a close structural relative of calcitonin gene-related peptide, the neuropeptide that migraine drugs are built to block. Thirty-six patients with migraine without aura were infused with pramlintide or human alpha-CGRP in a randomized, double-blind, two-way crossover, positive-controlled trial. 30 (88%) developed headache after pramlintide, against 33 (97%) after CGRP; 14 (41%) developed migraine-like attacks, against 19 (56%) after CGRP, and the pramlintide attacks had the same clinical character as the CGRP ones Ghanizada 2021. Human receptor pharmacology in the same paper placed the effect at an amylin receptor rather than the canonical CGRP receptor, and mice given amylin developed cutaneous hypersensitivity and light aversion. Nobody selling an amylin analog mentions this, and it is the single most compound-specific safety finding on this page: if you get migraines, this drug provokes them in about 4 of every 10 people who do, through the receptor it is designed to hit.
4. The calcitonin receptor, which nobody has looked at. Because the amylin receptor is a calcitonin receptor plus a RAMP Boyle 2022, chronic amylin agonism is chronic partial calcitonin agonism, and no published trial of pramlintide reports calcitonin, calcium or a bone-turnover marker. That is an absence, not a reassurance.
What does not transfer from the class block. The gallbladder signal in that block is a GLP-1 finding — relative risk 1.37 across 76 randomized trials and 103,371 patients, and 2.29 in weight-loss trials specifically He 2022. Pramlintide is not a GLP-1 and does not produce weight loss on that scale, so neither half of that risk applies to it in the form the block states. Nor does the thyroid C-cell rodent contraindication, which is a GLP-1 receptor labeling matter and has nothing to do with amylin.
Sources read for this page
- Boyle CN, Le Foll C, Lutz TA. Mediators of Amylin Action in Metabolic Control. Journal of Clinical Medicine 2022 · PMID 35456307
- Volcansek S, et al. Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. Diabetes Therapy 2025 · PMID 40332747
- Kern KA, et al. Chronic pramlintide decreases feeding via a reduction in meal size in male rats. Peptides 2024 · PMID 38493922
- Avgerinos I, et al. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. Diabetes, Obesity and Metabolism 2021 · PMID 33300282
- Sheehan A, et al. Pramlintide for post-bariatric hypoglycaemia. Diabetes, Obesity and Metabolism 2022 · PMID 35137513
- Ghanizada H, et al. Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients. Annals of Neurology 2021 · PMID 33772845
- Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism 2025 · PMID 41109426
- He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
Pramlintide — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Pramlintide — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Pramlintide moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Pramlintide in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Pramlintide
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Comprehensive Metabolic Panel (CMP) | Fasting glucose. With insulin, pramlintide causes severe hypoglycemia |
| HbA1c (Hemoglobin A1c) | The glycemic baseline |
| Fasting Insulin | The axis being modified |
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel covers these in one order — 11 markers, $148.05 with the discount applied.
Check results you already have → · All 103 markers A–Z
Pramlintide — frequently asked questions
What is Pramlintide?
Pramlintide (Symlin (amylin analog)) is a metabolic & fat loss research compound. Synthetic amylin analog — slows gastric emptying, suppresses glucagon, and curbs appetite; the original amylin drug, dosed at meals.
Is the full Pramlintide protocol on this page?
The reported research dose is on this page, along with how Pramlintide works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Pramlintide?
Pramlintide has an approximate half-life of ~48 min, which is part of what determines how often it's dosed.
What's the evidence behind Pramlintide?
Current evidence level: FDA-approved; human. Pramlintide is offered for research purposes only and is not an approved medicine.
What Pramlintide is used for
Pramlintide appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.